| Jennifer Ann Regan, MD, PHD | |
|
1740 Nw Maple St Ste 211, Issaquah, WA 98027-8127 | |
| (425) 395-0175 | |
| Not Available |
| Full Name | Jennifer Ann Regan |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 24 Years |
| Location | 1740 Nw Maple St Ste 211, Issaquah, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548571284 | NPI | - | NPPES |
| 125058610 | Other | IL | IL LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | MD60671179 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Asthma And Allergy Center | 6507759743 | 15 |
News Archive
APCER PHARMA executives will discuss and demonstrate their expertise in providing generic drug manufacturers with the best in class pharmacovigilance/drug safety, regulatory and risk management services at the GPhA Annual Meeting, February 16-18, at the Ritz-Carlton in Naples, Florida. APCER will be in Booth #27.
Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).
Pressure Point Inc. has developed an effective 72 hour low-cost, FDA Market Cleared dermal device, which uses an advanced acupressure approach for longer-acting prophylactic results in reducing the occurrences of postoperative nausea and vomiting.
Around one in four Montrealers take some kind of anti-depressant, and according to new research, the drugs are passing into the waterways and affecting fish. The findings are internationally significant as the city's sewage treatment system is similar to that in use in other major cities, and moreover, it is reputed to be the third largest treatment system in the world.
› Verified 2 days ago
| Entity Name | The Association Of University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
APCER PHARMA executives will discuss and demonstrate their expertise in providing generic drug manufacturers with the best in class pharmacovigilance/drug safety, regulatory and risk management services at the GPhA Annual Meeting, February 16-18, at the Ritz-Carlton in Naples, Florida. APCER will be in Booth #27.
Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).
Pressure Point Inc. has developed an effective 72 hour low-cost, FDA Market Cleared dermal device, which uses an advanced acupressure approach for longer-acting prophylactic results in reducing the occurrences of postoperative nausea and vomiting.
Around one in four Montrealers take some kind of anti-depressant, and according to new research, the drugs are passing into the waterways and affecting fish. The findings are internationally significant as the city's sewage treatment system is similar to that in use in other major cities, and moreover, it is reputed to be the third largest treatment system in the world.
› Verified 2 days ago
| Entity Name | Northwest Asthma & Allergy Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760620462 PECOS PAC ID: 6507759743 Enrollment ID: O20040209000462 |
News Archive
APCER PHARMA executives will discuss and demonstrate their expertise in providing generic drug manufacturers with the best in class pharmacovigilance/drug safety, regulatory and risk management services at the GPhA Annual Meeting, February 16-18, at the Ritz-Carlton in Naples, Florida. APCER will be in Booth #27.
Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).
Pressure Point Inc. has developed an effective 72 hour low-cost, FDA Market Cleared dermal device, which uses an advanced acupressure approach for longer-acting prophylactic results in reducing the occurrences of postoperative nausea and vomiting.
Around one in four Montrealers take some kind of anti-depressant, and according to new research, the drugs are passing into the waterways and affecting fish. The findings are internationally significant as the city's sewage treatment system is similar to that in use in other major cities, and moreover, it is reputed to be the third largest treatment system in the world.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Ann Regan, MD, PHD 9725 3rd Ave Ne Ste 500, Seattle, WA 98115-2024 Ph: (206) 527-1200 | Jennifer Ann Regan, MD, PHD 1740 Nw Maple St Ste 211, Issaquah, WA 98027-8127 Ph: (425) 395-0175 |
News Archive
APCER PHARMA executives will discuss and demonstrate their expertise in providing generic drug manufacturers with the best in class pharmacovigilance/drug safety, regulatory and risk management services at the GPhA Annual Meeting, February 16-18, at the Ritz-Carlton in Naples, Florida. APCER will be in Booth #27.
Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).
Pressure Point Inc. has developed an effective 72 hour low-cost, FDA Market Cleared dermal device, which uses an advanced acupressure approach for longer-acting prophylactic results in reducing the occurrences of postoperative nausea and vomiting.
Around one in four Montrealers take some kind of anti-depressant, and according to new research, the drugs are passing into the waterways and affecting fish. The findings are internationally significant as the city's sewage treatment system is similar to that in use in other major cities, and moreover, it is reputed to be the third largest treatment system in the world.
› Verified 2 days ago